Evaluating patient reported outcomes in the treatment practice of patients with rheumatoid arthritis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25449

Enrollment

300

Registered

2013-08-30

Start date

2013-09-10

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient Reported Outcomes, PROs Rheumatoid Arthritis, RA Intensive outpatient management Tight Control Treat to target (T2T)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Adults with reumatoïde artritis treated with biologicals, such as TNFα-blockers (etanercept, adalimumab, infliximab etc.), interleukine-I-blockers, the B-celblocker rituximab, and the T-celactivationblocker and anti CTLA4 (abatacept).

Exclusion criteria

Exclusion criteria: non RA patients, no biological treatment, non adult,

Design outcomes

Primary

Measure	Time frame
Patient reported outcomes (RAPID-3) and DAS28	—

Secondary

Measure	Time frame
Side effects	—

Outcome results